These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18179848)

  • 21. New tripodal hydroxypyridinone based chelating agents for Fe(III), Al(III) and Ga(III): Synthesis, physico-chemical properties and bioevaluation.
    Grazina R; Gano L; Sebestík J; Amelia Santos M
    J Inorg Biochem; 2009 Feb; 103(2):262-73. PubMed ID: 19062099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
    Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
    Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Iron metabolism disorders].
    Bommer M; Heimpel H
    Pharm Unserer Zeit; 2009; 38(3):242-50. PubMed ID: 19396907
    [No Abstract]   [Full Text] [Related]  

  • 25. Cycloaddition of 2(1H)-pyridones having a methoxycarbonyl group to 1,3-butadiene derivatives.
    Fujita R; Hoshino M; Tomisawa H; Matsuzaki H; Hongo H
    Chem Pharm Bull (Tokyo); 2001 Apr; 49(4):497-500. PubMed ID: 11310684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and phytotoxic activity of new pyridones derived from 4-hydroxy-6-methylpyridin-2(1H)-one.
    Demuner AJ; Valente VM; Barbosa LC; Rathi AH; Donohoe TJ; Thompson AL
    Molecules; 2009 Dec; 14(12):4973-86. PubMed ID: 20032871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of cardiac and hepatic iron overload in thalassaemic patients by magnetic resonance: a four year observational study.
    Candini G; Lappi S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():204-7. PubMed ID: 19337179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
    Kim YR; Kim JS; Cheong JW; Song JW; Min YH
    Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron overload in hematopoietic cell transplantation.
    Majhail NS; Lazarus HM; Burns LJ
    Bone Marrow Transplant; 2008 Jun; 41(12):997-1003. PubMed ID: 18438425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric iron overload.
    Cohen AR
    Clin Adv Hematol Oncol; 2007 Aug; 5(8):601-2. PubMed ID: 17982399
    [No Abstract]   [Full Text] [Related]  

  • 31. Combined chelation of bi-functional bis-hydroxypiridinone and mono-hydroxypiridinone: synthesis, solution and in vivo evaluation.
    Gama S; Gil M; Gano L; Farkas E; Amélia Santos M
    J Inorg Biochem; 2009 Feb; 103(2):288-98. PubMed ID: 19091421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessmrent of iron overload in thalassaemic patients by magnetic resonance imaging: a pilot study.
    Kumar P; Jagannathan NR; Choudhry VP
    J Indian Med Assoc; 2007 Oct; 105(10):561-4, 591. PubMed ID: 18383951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.
    Majhail NS; DeFor T; Lazarus HM; Burns LJ
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):790-4. PubMed ID: 18541198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
    Chowdhury MA; Abdellatif KR; Dong Y; Das D; Suresh MR; Knaus EE
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6138-41. PubMed ID: 18945614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
    Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
    Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
    [No Abstract]   [Full Text] [Related]  

  • 36. Design, synthesis, and thrombin-inhibitory activity of pyridin-2-ones as P2/P3 core motifs.
    Hanessian S; Simard D; Bayrakdarian M; Therrien E; Nilsson I; Fjellström O
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1972-6. PubMed ID: 18289852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current concepts in the management of transfusional iron overload].
    Thuret I; Barlogis V; Michel G
    Arch Pediatr; 2009 Jun; 16(6):559-61. PubMed ID: 19541084
    [No Abstract]   [Full Text] [Related]  

  • 38. One-pot synthesis of 2-pyridones via chemo- and regioselective tandem Blaise reaction of nitriles with propiolates.
    Chun YS; Ryu KY; Ko YO; Hong JY; Hong J; Shin H; Lee SG
    J Org Chem; 2009 Oct; 74(19):7556-8. PubMed ID: 19778084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe iron overload in Blackfan-Diamond anemia: a case-control study.
    Roggero S; Quarello P; Vinciguerra T; Longo F; Piga A; Ramenghi U
    Am J Hematol; 2009 Nov; 84(11):729-32. PubMed ID: 19810012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superoxide scavenging activity of pirfenidone-iron complex.
    Mitani Y; Sato K; Muramoto Y; Karakawa T; Kitamado M; Iwanaga T; Nabeshima T; Maruyama K; Nakagawa K; Ishida K; Sasamoto K
    Biochem Biophys Res Commun; 2008 Jul; 372(1):19-23. PubMed ID: 18468515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.